Browse All

Current Filters

CLEAR FILTER x

TITLE

Effects of Semaglutide on Alzheimer’s Disease-related Biological Processes: Results from a Biofluid Biomarker and Multiomics Immunophenotyping Phase 3 Study in Patients with Early Alzheimer’s Disease After 12 Weeks of Treatment

Semaglutide Concentration in Cerebrospinal Fluid from Patients with Early Alzheimer’s Disease After 12 Weeks of Subcutaneous Treatment

Top-line Results from evoke and evoke+: Two Phase 3, Randomized, Placebo-controlled Trials of Semaglutide in Participants with Early-stage Symptomatic Alzheimer’s Disease